Matthew S. Scarano

Cooley advised Core Scientific (Nasdaq: CORZ), a leader in digital infrastructure for high-density colocation, in connection with an offering of $3.3 billion aggregate principal amount of 7.750% senior secured notes due 2031 issued by its wholly-owned subsidiary, Core Scientific Finance I LLC, at an issue price equal to 99.250% of the principal amount thereof.

Cooley advised Neurocrine, a leading biopharmaceutical company, on its agreement to acquire Soleno, a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases, for $2.9 billion.

Cooley advised Core Scientific, a leader in digital infrastructure for high-density colocation, on a $1 billion 364-day loan facility with Morgan Stanley and JPMorgan Chase Bank.

Cooley advised Pulmonx, a global leader in minimally invasive treatments for chronic obstructive pulmonary disease, on a $60 million credit facility with Perceptive Advisors. Lawyers John McKenna, Matthew Scarano and Yoni Horn led a Cooley team advising Pulmonx.

Cooley advised Enlaza Therapeutics, the first covalent biologics platform company, on its multi-target drug discovery collaboration with Vertex Pharmaceuticals, to utilize Enlaza’s proprietary War-Lock technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia.